bioAffinity Technologies Shares to Reverse Split on Monday, August 24th (NASDAQ:BIAF)

bioAffinity Technologies, Inc. (NASDAQ:BIAF)’s stock is going to reverse split on Monday, August 24th. The 1-15 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, August 23rd.

bioAffinity Technologies Trading Down 2.2%

NASDAQ BIAF traded down $0.01 during midday trading on Thursday, hitting $0.40. The company had a trading volume of 3,329,193 shares, compared to its average volume of 9,021,737. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.44 and a quick ratio of 1.41. The firm has a 50-day moving average price of $0.71 and a 200-day moving average price of $1.59. bioAffinity Technologies has a twelve month low of $0.33 and a twelve month high of $13.50.

bioAffinity Technologies (NASDAQ:BIAF) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.10) by $1.46. The business had revenue of $1.51 million for the quarter, compared to analysts’ expectations of $1.70 million. bioAffinity Technologies had a negative net margin of 257.30% and a negative return on equity of 220.52%.

Analyst Ratings Changes

A number of research firms recently commented on BIAF. Wall Street Zen raised bioAffinity Technologies from a “sell” rating to a “hold” rating in a research note on Monday, August 10th. Weiss Ratings restated a “sell (e+)” rating on shares of bioAffinity Technologies in a report on Monday, July 20th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in BIAF. Scientech Research LLC purchased a new position in bioAffinity Technologies in the 3rd quarter worth approximately $49,000. Geode Capital Management LLC bought a new position in bioAffinity Technologies in the 4th quarter worth $36,000. Finally, J. Safra Sarasin Holding AG purchased a new stake in bioAffinity Technologies in the first quarter worth about $164,000. Institutional investors own 1.64% of the company’s stock.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.